Pregnancy Clinical Trial
Official title:
Determination Glycine Requirements During Healthy Pregnancy Using the Indicator Amino Acid Oxidation (IAAO) Technique
It is important that pregnant women eat an adequate amount of protein to ensure healthy growth and development of the fetus. Amino acids are the building blocks of the body's protein. Glycine is an amino acid that can be made in the body, but under certain metabolic circumstances (e.g. pregnancy) the body's needs may be higher and thus glycine must be obtained from the diet. Currently, it is not known how much glycine may be needed from the diet during pregnancy. We plan to study dietary glycine requirements in healthy pregnant women, during early and late gestation. We will do this using a modern, safe and quick method.
Purpose:
To determine the dietary glycine requirement in healthy pregnant women during mid (20 - 30
weeks) and late (31 - 40 weeks) gestation.
Hypothesis:
We hypothesize that there is a dietary requirement for glycine during pregnancy due to an
increased metabolic demand. With increased glycine intake we hypothesize to observe an
increase in protein synthesis, as measured by the indicator amino acid oxidation (IAAO)
method.
Justification:
Inadequate protein intake during pregnancy may cause intrauterine growth restriction, which
is associated with increased risk of chronic diseases later in life. Currently, the dietary
intake recommendations for amino acids are greatly based on nitrogen balance studies of
non-pregnant adults. There is little scientific information regarding dietary glycine needs
during different stages of pregnancy, despite empirical evidence indicating gestational
differences in protein metabolism.
Objectives:
The main objective of the current study is to determine the glycine requirement using the
minimally invasive indicator amino acid oxidation (IAAO) method in healthy pregnant women.
Our second objective is to compare the glycine requirement during mid (20-30 weeks gestation)
and late (31 - 40 weeks gestation) stages of pregnancy.
Research methods:
We will recruit a minimum of 18 pregnant women who may take part in 2 study days in both
gestational stages, for a total of 72 study days. Potential participants will meet us for a
preliminary assessment where we will evaluate their eligibility to participate in the study.
The preliminary study will take approximately 1 hr during which we will examine body
composition (bioelectrical impedance, skin-fold measurements, height and weight), resting
energy expenditure (indirect calorimetry), blood glucose (glucometer), and medical history
(questionnaire). Fasted blood glucose above 6.7 mmol/L is indicative of gestational diabetes.
Participants with fasted blood glucose concentrations above 6.7 mmol/L will be referred to
follow-up with their primary health care provider (see letter to physician).
We will test the participants urine using a dipstick, to assess whether proteinurea is
present. If there is an indication of proteinurea we will refer the participant to their
primary physician (See letter to physician - Urine results).
We will collect a 3 day diet record to determine usual food intake and food preferences.
Based on the 3 day food record we will prescribe a standardized diet two days prior to the
study day to ensure protein intake of 1.5 g/kg/d and energy intake of 1.7 x resting energy.
During each study day, eligible participants will randomly receive 1 of 36 test glycine
intakes during both mid and late pregnancy, ranging from 10 to 100 mg/kg/d. Each subject may
participate in 2 study days between 20-30 weeks gestation and 2 study days between 31 - 40
weeks gestation, for a total of 4 study days. The test glycine intakes will contain a
crystalline L-amino acid mixture based on the composition of egg protein, except for glycine.
The test glycine intake will be administered in an experimental diet, along with enough
non-protein energy to meet 1.7 x resting energy expenditure of each participant. The diet
will be provided as 8 meals, each representing 1/12th of the participant's daily intake
requirement. These meals will be provided over the course of an 8 hour study day. A stable
isotope tracer will be added to the 5th - 8th meal. We will measure the rate of oxidation of
this tracer in expired breath (F13CO2), and flux of this tracer by its enrichment in urine.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02566005 -
A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor
|
N/A |